Ginkgo Bioworks Holdings, Inc. (DNA) tiene un P/E histórico negativo de -1.1, lo que significa que la empresa actualmente no es rentable en base a los últimos doce meses (TTM). El rendimiento de ganancias histórico es -88.12%.
Criterios demostrados por esta página:
Puntuación General SharesGrow: 45/100 con 2/7 criterios aprobados.
| Year | P/E (TTM) | Ratio PEG | Ratio P/B | Ratio P/S | Rendimiento por Dividendo |
|---|---|---|---|---|---|
| 2019 | -97.4 | 0.00 | 23.58 | 214.60 | - |
| 2020 | -101.2 | 23.33 | 27.77 | 167.14 | - |
| 2021 | -6.0 | 0.00 | 7.28 | 34.90 | - |
| 2022 | -1.3 | 0.20 | 1.63 | 5.93 | - |
| 2023 | -3.7 | 0.06 | 2.99 | 13.05 | - |
| 2024 | -0.9 | 0.02 | 0.71 | 2.24 | - |
| 2025 | -1.5 | 0.03 | 0.91 | 2.71 | - |
| Year | EPS (Diluido) | Ingresos | Ingreso Neto | Margen Neto |
|---|---|---|---|---|
| 2001 | $0.00 | $98.29M | $0.00 | 0% |
| 2019 | $-4.15 | $54.18M | $-119.33M | -220.2% |
| 2020 | $-4.00 | $76.66M | $-126.61M | -165.2% |
| 2021 | $-55.53 | $313.84M | $-1.83B | -583.1% |
| 2022 | $-50.20 | $477.71M | $-2.1B | -440.6% |
| 2023 | $-18.40 | $251.46M | $-892.87M | -355.1% |
| 2024 | $-10.54 | $227.04M | $-547.03M | -240.9% |
| 2025 | $-5.64 | $170.16M | $-312.76M | -183.8% |
| Year | EPS (Prom.) | Rango EPS | Ingresos (Prom.) | Rango de Ingresos | Analistas |
|---|---|---|---|---|---|
| 2026 | $-4.43 | $-4.55 – $-4.29 | $159.47M | $155.66M – $162.94M | 2 |
| 2027 | $-3.86 | $-4.69 – $-3.03 | $158.5M | $154.71M – $161.96M | 2 |
| 2028 | $-3.18 | $-3.27 – $-3.08 | $296.4M | $289.32M – $302.86M | 1 |
| 2029 | $-2.24 | $-2.30 – $-2.17 | $369.1M | $360.28M – $377.14M | 1 |
